Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Inebilizumab (Primary)
- Indications Scleroderma; Systemic scleroderma
- Focus Adverse reactions
- Sponsors MedImmune
- 31 Oct 2021 Results (n=213) assessing population pharmacokinetic modeling of inebilizumab from a pivotal study (NCT02200770) in adult subjects with neuromyelitis optica spectrum disorders and two early-stage studies (NCT00946699 and NCT01585766) in subjects with systemic sclerosis or relapsing multiple sclerosis were pooled and simultaneously analyzed using a population approach, published in the Clinical Pharmacokinetics.
- 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Oct 2014 New trial record